TY - JOUR AU - Alter, M. J. AU - Kruszon-Moran, D. AU - Nainan, O. V. AU - McQuillan, G. M. AU - Gao, F. AU - Moyer, L. A. PY - 1999 DA - 1999// TI - The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. JO - N Engl J Med VL - 341 ID - Alter1999 ER - TY - JOUR AU - Hoofnagle, J. H. PY - 1997 DA - 1997// TI - Hepatitis C: The clinical spectrum of disease. JO - Hepatology VL - 26 UR - https://doi.org/10.1002/hep.510260703 DO - 10.1002/hep.510260703 ID - Hoofnagle1997 ER - TY - CHAP AU - Cotler, S. J. AU - Wartelle, C. F. AU - Larson, A. M. AU - Gretch, D. R. AU - Jensen, D. M. AU - Carithers, R. L. PY - 2000 DA - 2000// TI - Pretreatment symptoms and dosing regimen predict side effects of interferon therapy for hepatitis C. BT - J Viral Hepat ID - Cotler2000 ER - TY - JOUR AU - Kiyosawa, K. AU - Sodeyama, T. AU - Tanaka, E. AU - Gibo, Y. AU - Yoshizawa, K. AU - Nakano, Y. PY - 1990 DA - 1990// TI - Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. JO - Hepatology VL - 12 UR - https://doi.org/10.1002/hep.1840120409 DO - 10.1002/hep.1840120409 ID - Kiyosawa1990 ER - TY - JOUR AU - Tong, M. J. AU - El-Farra, N. S. AU - Reikes, A. R. AU - Co, R. L. PY - 1995 DA - 1995// TI - Clinical outcomes after transfusion-associated hepatitis C. JO - N Engl J Med VL - 332 UR - https://doi.org/10.1056/NEJM199506013322202 DO - 10.1056/NEJM199506013322202 ID - Tong1995 ER - TY - JOUR AU - Poynard, T. AU - Bedossa, P. AU - Opolon, P. PY - 1997 DA - 1997// TI - Natural history of liver fibrosis progression in patients with chronic hepatitis C. JO - Lancet VL - 349 UR - https://doi.org/10.1016/S0140-6736(96)07642-8 DO - 10.1016/S0140-6736(96)07642-8 ID - Poynard1997 ER - TY - JOUR AU - Poynard, T. AU - Marcillin, P. AU - Lee, S. S. AU - Niederau, C. AU - Minuk, G. S. AU - Ideo, G. PY - 1998 DA - 1998// TI - Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. JO - Lancet VL - 352 UR - https://doi.org/10.1016/S0140-6736(98)07124-4 DO - 10.1016/S0140-6736(98)07124-4 ID - Poynard1998 ER - TY - JOUR AU - McHutchison, J. G. AU - Gordon, S. C. AU - Schiff, E. R. AU - Shiffman, M. L. AU - Lee, W. M. AU - Rustgi, V. K. PY - 1998 DA - 1998// TI - Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. JO - N Engl J Med VL - 339 UR - https://doi.org/10.1056/NEJM199811193392101 DO - 10.1056/NEJM199811193392101 ID - McHutchison1998 ER - TY - JOUR AU - McHutchinson, J. G. AU - Poynard, T. PY - 2000 DA - 2000// TI - Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. JO - Semin Liver Dis VL - 19 ID - McHutchinson2000 ER - TY - JOUR AU - Bonkovsky, H. L. AU - Wooley, J. M. PY - 1999 DA - 1999// TI - Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. JO - Hepatology VL - 29 UR - https://doi.org/10.1002/hep.510290124 DO - 10.1002/hep.510290124 ID - Bonkovsky1999 ER - TY - JOUR AU - Marcellin, P. AU - Boyer, N. AU - Gervais, A. AU - Martinot, M. AU - Pouteau, M. AU - Castelnau, C. PY - 1997 DA - 1997// TI - Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. JO - Ann Intern Med VL - 127 UR - https://doi.org/10.7326/0003-4819-127-10-199711150-00003 DO - 10.7326/0003-4819-127-10-199711150-00003 ID - Marcellin1997 ER - TY - JOUR AU - Ware, J. E. AU - Bayliss, M. S. AU - Mannocchia, M. AU - Davis, G. L. PY - 1999 DA - 1999// TI - Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. JO - Hepatology VL - 30 UR - https://doi.org/10.1002/hep.510300203 DO - 10.1002/hep.510300203 ID - Ware1999 ER - TY - JOUR AU - Torrance, G. W. PY - 1986 DA - 1986// TI - Measurement of health state utilities for economic appraisal: A review. JO - J Health Econ VL - 5 UR - https://doi.org/10.1016/0167-6296(86)90020-2 DO - 10.1016/0167-6296(86)90020-2 ID - Torrance1986 ER - TY - JOUR AU - Torrance, G. W. PY - 1987 DA - 1987// TI - Utility approach to measuring health-related quality of life. JO - J Chronic Dis VL - 40 UR - https://doi.org/10.1016/0021-9681(87)90019-1 DO - 10.1016/0021-9681(87)90019-1 ID - Torrance1987 ER - TY - JOUR AU - Davis, G. L. AU - Esteban-Mur, R. AU - Rustigi, V. AU - Hoefs, J. AU - Gordon, S. C. AU - Trepo, C. PY - 1998 DA - 1998// TI - Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. JO - N Engl J Med VL - 339 UR - https://doi.org/10.1056/NEJM199811193392102 DO - 10.1056/NEJM199811193392102 ID - Davis1998 ER - TY - JOUR AU - Owens, D. K. AU - Cardinalli, A. B. AU - Nease, R. F. PY - 1997 DA - 1997// TI - Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. JO - Qual Life Res VL - 6 UR - https://doi.org/10.1023/A:1026473613487 DO - 10.1023/A:1026473613487 ID - Owens1997 ER - TY - JOUR AU - Shehab, T. M. AU - Sonnad, S. S. AU - Jeffries, M. AU - Gunaratum, N. AU - Lok, A. S. F. PY - 1999 DA - 1999// TI - Current practice patterns of primary care physicians in the management of patients with hepatitis C. JO - Hepatology VL - 30 UR - https://doi.org/10.1002/hep.510300328 DO - 10.1002/hep.510300328 ID - Shehab1999 ER - TY - JOUR AU - Manns, M. P. AU - McHutchinson, J. G. AU - Gordon, S. AU - Rustgi, V. AU - Shiffman, M. L. AU - Lee, W. M. PY - 2000 DA - 2000// TI - Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial (abstract). JO - Hepatology VL - 32 UR - https://doi.org/10.1053/jhep.2000.19149 DO - 10.1053/jhep.2000.19149 ID - Manns2000 ER - TY - JOUR AU - Treadwell, J. R. AU - Kearney, D. AU - Davila, M. PY - 2000 DA - 2000// TI - Health profile preferences of hepatitis C patients. JO - Dig Dis Sci VL - 45 UR - https://doi.org/10.1023/A:1005420828332 DO - 10.1023/A:1005420828332 ID - Treadwell2000 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/content/backmatter/1471-230X-1-6-b1.pdf UR - http://www.biomedcentral.com/content/backmatter/1471-230X-1-6-b1.pdf ID - ref20 ER -